<DOC>
	<DOCNO>NCT02147925</DOCNO>
	<brief_summary>The aim study explore effectiveness liraglutide combine metformin non-alcoholic fatty-liver disease patient type 2 diabetes mellitus ( T2DM ) compare sitagliptin insulin glargine combination metformin .</brief_summary>
	<brief_title>Efficacy Study Liraglutide vs.Sitagliptin vs. Glargine Liver Fat T2DM Subjects</brief_title>
	<detailed_description>This 26-week , randomize , open-label , active control , parallel group , multi-centre trial.To compare change intrahepatic lipid ( IHL ) measure magnetic resonance spectroscopy ( MRS ) MRI estimate proton density fat fraction ( MRI-PDFF ) measure MRI IDEAL IQ ( Iterative Decomposition water andfat Echo Asymmetryand Least-squares estimation ) type 2 diabetic patient non-alcoholic fatty-liver disease 26-week treatment liraglutide , sitagliptin insulin glargine per day combine metformin.The primary endpoint define intrahepatic lipid ( IHL ) measure magnetic resonance spectroscopy ( MRS ) MRI-PDFF measure MRI IDEAL IQ .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Recorded Type 2 diabetes diagnose least 3 month study ; At least 3 month treatment stable dose（≧1500mg/d）of metformin study 6.5 % &lt; HbA1c ≤10 % Clinically diagnose simple liver steatosis 3075 year old Female subject postmenopausal , surgically sterile , use contraceptive 3 month screen continue throughout study ; BMI 20~35 kg/m2 history stable body weight ( ≤10 % variation ≥3 month ) intrahepatic lipid ( IHL ) &gt; 10 % Type 1 diabetes Treatment within last 3 month Thiazolidinediones ( TZDs ) , orlistat , insulin , history incretin base therapy drug associate hepatic steatosis ( include limited glucocorticoid , tamoxifen , amiodarone methotrexate ) History current episode pancreatitis disease pancrea ; Impaired liver function , define plasma alanine transaminase ( ALT ) &gt; 2.5 time upper normal limit Moderate severe renal insufficiency define MDRD formula glomerular filtration rate &lt; 60ml/min/1.73m2 Weekly alcohol intake &gt; 14 unit woman &gt; 21 unit men Any history liver disease include metabolic autoimmune liver diseases viral hepatitis History family history medullary thyroid cancer ( MTC ) , multiple endocrine neoplasia type 2 ( MEN2 ) Congestive heart failure ( NYHA III~IV ) Severe gastricintestinal disease Pregnancy and/or intention become pregnant Known proliferative retinopathy maculopathy require acute treatment judge Investigator ; Use nonherbal Chinese medicine nonherbal local medicine unknown/unspecified content . Herbal traditional Chinese medicine local herbal medicine may , Investigator 's discretion , continue throughout trial unchanged dose</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Non-alcoholic fatty liver disease</keyword>
	<keyword>Glucagon-like peptide-1 receptor agonist</keyword>
	<keyword>Diabetes mellitus , type 2</keyword>
</DOC>